Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Sarcoma 2Gynecologic 2Gastrointestinal 2Other solid neoplasm 1Head & Neck 1Genitourinary 1

Conditions

Sarcoma 1Ovarian Neoplasms 1Neoplasms 1Mesothelioma 1Colorectal Neoplasms 1

Interventions

pembrolizumab 8fludarabine 4Cyclophosphamide 4amatuximab 3Thiotepa 3Nivolumab 3Ipilimumab 3Hyperthermic Intraperitoneal Chemotherapy 3Filgrastim 3Carboplatin 3budigalimab 2belinostat 2SS1(dsFv)PE38 2Platinum 2Peripheral Blood Stem Cell Transplantation 2Cisplatin 21,2-diaminocyclohexaneplatinum II citrate 2venetoclax 1talazoparib 1sodium thiosulfate 1rovalpituzumab tesirine 1ribociclib 1rebastinib 1obinutuzumab 1naptumomab estafenatox 1fludarabine phosphate 1epacadostat 1durvalumab 1bosutinib 1aldesleukin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × OSI 930 × Other solid neoplasm × Clear all
NCT00603356 2011-09-27

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

Astellas Pharma Inc

Phase 1 Completed
60 enrolled
GastrointestinalGynecologicOther solid neoplasmSarcomaThoracic

Mesothelioma, Neoplasms, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡